Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood.
Twenty-two children with immune thrombocytopenic purpura (ITP) with long-lasting thrombocytopenia, adversely affecting their quality of life, were treated with a reduced rituximab regimen in order to eliminate B cells producing anti-platelet antibody. A single dose of rituximab resulted in a response rate similar to that reported for cases in which 4 doses of rituximab were used.
Taube
Tillmann
T
Schmid
Hansjörg
H
Reinhard
Harald
H
von Stackelberg
Arend
A
Overberg
Ursula Schulte
US
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001402:B-Lymphocytes / Q000378:metabolism; D001792:Blood Platelets / Q000737:chemistry / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab